· Tagrisso +10%, robust demand across indications, leadership in 1L combo market · Imfinzi +37%, Imjudo +26%, broad-based growth across lung, Gl, GU indications · Calquence +17%, 1L CLL class leader in all major markets, growing share in US · Enhertu +46%, strong mBC growth, continued strength in CN Truqap +41%, strong demand growth ex-US, rapidly achieved 2L peak share in US · Datroway $40m, early launch momentum in later line EGFRm lung cancer US (Enhertu DESTINY-BreastO9, Imfinzi MATTERHORN), EU (Enhertu DESTINY- GastricO4), CN (Enhertu DESTINY-GastricO4, DESTINY-BreastO6, Imfinzi PACIFIC-5)
原图定位
